Migraine and Fish Oil

Considering the importance of migraine as the seventh cause of disability globally, this study was conducted to evaluate the effectiveness of fish oil and omega-3 polyunsaturated fatty acids (PUFA) on migraine. In this review article, we included all clinical trials and review articles from four databases (Pubmed, the Cochrane database of systematic reviews, Scopus, and Clinicalkey), published from January 1, 1990, to August 7, 2018, in which the treatment effects of fish oil or PUFA for the prevention or control of migraine attacks, either in basic science or clinical field, have been studied. At first, 54 articles or book chapters were found, and after reviewing their study design, 13 clinical trials and review articles were included in the study. Most of reviewed articles, including five clinical trials and four review articles, represented the positive impact of fish oil and omega-3 PUFA for improvement in frequency, intensity, or duration of migraine headache; however, a definite daily dosage and duration of treatment have not been defined. Although the evidence that supports the positive impact of fish oil and PUFA in the prevention and control of migraine is frequent, more evidence and longitudinal study designs are required to confirm the positive impact of fish oil on migraine. Furthermore, research is needed to define an appropriate daily dosage and treatment duration of fish oil and PUFA in migraine patients.


1. Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache 2018; 58(Suppl 3): 218-29. [CrossRef]

2. Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol 2018; 17: 174-82. [CrossRef]

3. Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci 2015; 35(17): 6619-29. [CrossRef]

4. Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine?. Brain Behav 2018; 8(6): e00950. [CrossRef]

5. Dodick DW. Migraine. Lancet 2018; 391: 1315-30. [CrossRef]

6. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the united states: figures and trends from government health studies. Headache 2018; 58(4): 496-505. [CrossRef]

7. Coeytaux RR, Mann JD. Headache. 2018; Chapter 12: 108. Available from: www. clinicalkey.com. [CrossRef]

8. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053): 1545-602. [CrossRef]

9. Sullivan A, Cousins S, Ridsdale L. Psychological interventions for migraine: a systematic review. J Neurol 2016; 263(12): 2369-77. [CrossRef]

10. Bulaj G. Combining non-pharmacological treatments with pharmacotherapies for neurological disorders: a unique interface of the brain, drug–device, and intellectual property. Front Neurol 2014; 5: 126. [CrossRef]

11. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus 2016; 5: 637. [CrossRef]

12. Pizzorno JE, Paul C, Schauss AG. Fish Oils (Omega-3 Fatty Acids, Docosahexaenoic Acid, Eicosapentaenoic Acid, Dietary Fish, and Fish Oils) in Textbook of Natural Medicine. 4th ed. St. Louis, MO: Elsevier Churchill Livingstone; 2013: chap 91. [CrossRef]

13. Soares AA, Louçana PMC, Nasi EP, Sousa KMH, Sá OMS3, Silva-Néto RP. A double- blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA -3) for the prevention of migraine in chronic migraine patients using amitriptyline. Nutr Neurosci 2018; 21(3): 219-23. [CrossRef]

14. Maghsoumi-Norouzabad L, Mansoori A, Abed R, Shishehbor F. Effects of omega-3 fatty acids on the frequency, severity, and duration of migraine attacks: A systematic review and meta-analysis of randomized controlled trials. Nutr Neurosci 2017; 30: 1-10. [CrossRef]

15. Ramsden CE, Faurot KR, Zamora D, Suchindran CM, Macintosh BA, Gaylord S, et al. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: A randomized trial. Pain 2013; 154(11): 10. [CrossRef]

16. Tajmirriahi M, Sohelipour M, Basiri K, Shaygannejad V, Ghorbani A, Saadatnia M. The effects of sodium valproate with fish oil supplementation or alone in migraine prevention: A randomized single-blind clinical trial. Iran J Neurol 2012; 11(1): 21-4.

17. Martin VT, Vij B. Diet and Headache: Part 2. Headache 2016; 56(9): 1553-62. [CrossRef]

18. Simopoulos A. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002; 21(6): 495-505. [CrossRef]

19. McCarty M. Magnesium taurate and fish oil for prevention of migraine. Med Hypotheses 1996; 47: 461-6. [CrossRef]

20. Harel Z, Gascon G, Riggs S, Vaz R, Brown W, Exil G. Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents. J Adolesc Health 2002; 31(2): 154-61. [CrossRef]

21. Pradalier A, Bakouche P, Baudesson G, Delage A, Cornaille-Lafage G, Launay JM, et al. Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia 2001; 21(8): 818-22. [CrossRef]

22. Fayyazi A, Khajeh A, Ghazavi A, Sangestani M. Omega 3 in childhood migraines: a double blind randomized clinical trial. Iran J Child Neurol 2016; 10(1): 9-13.

23. Rajapakse T, Pringsheim T. Nutraceuticals in migraine: a summary of existing guidelines for use. Headache 2016; 56(4): 808-16. [CrossRef]

24. Soveyd N, Abdolahi M1, Djalali M, Hatami M, Tafakhori A, Sarraf P, et al. The combined effects of omega -3 fatty acids and nano-curcumin supplementation on intercellular adhesion molecule-1 (ICAM-1) gene expression and serum levels in migraine patients. CNS Neurol Disord Drug Targets 2018; 16(10): 1120-6. [CrossRef]

25. Abdolahi M, Tafakhori A, Togha M, Okhovat AA, Siassi F, Eshraghian MR, et al. The synergistic effects of omega-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-alpha gene expression and serum level in migraine patients. Immunogenetics 2017; 69(6): 371-8. [CrossRef]

26. Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and structural changes in the brain: a systematic review and meta-analysis. Neurology 2013; 81(14): 1260-8. [CrossRef]

27. Calder P. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans 2017; 45(5): 1105-15. [CrossRef]

28. Laye S, Nadjar A, Joffre C, Bazinet RP. Anti-inflammatory effects of omega-3 fatty acids in the brain: physiological mechanisms and relevance to pharmacology. Pharmacol Rev 2018; 70(1): 12-38. [CrossRef]

29. Zhang W, Wang H, Zhang H, Leak RK, Shi Y, Hu X, et al. Dietary supplementation with omega-3 polyunsaturated fatty acids robustly promotes neurovascular restorative dynamics and improves neurological functions after stroke. Exp Neurol 2015; 272: 170-80. [CrossRef]

30. Elinder F, Liin SI. Actions and mechanisms of polyunsaturated fatty acids on voltage-gated ion channels. Front Neurol 2017; 8: 43. [CrossRef]

31. La Rovere MT, Christensen JH. The autonomic nervous system and cardiovascular disease: role of n-3 PUFAs. Vascul Pharmacol 2015; 71: 1-10. [CrossRef]

32. Limbu R, Cottrell GS, McNeish AJ. Characterisation of the vasodilation effects of DHA and EPA, n-3 PUFAs (fish oils), in rat aorta and mesenteric resistance arteries. PloS one 2018; 13(2): e0192484. [CrossRef]